Dingwei Ye

14PUBLICATIONS
27CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer cell biologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 13, 2026
TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways.

|Jun 05, 2026
TSC22D4 drives clear cell renal cell carcinoma progression and therapy resistance by stabilizing NRF2 through KEAP1 disruption.

|Jun 01, 2026
APOL3 Orchestrates Metastasis and Enzalutamide Resistance via STAT3-DAB2IP Signaling in Prostate Cancer.

|Mar 14, 2026
DPP9 inhibition boosts antitumor immunity by disrupting BRISC-mediated PD-L1 expression in clear cell renal cell carcinoma.

Wei Zhang, Yue Wang, Tao Feng

|Oct 10, 2025
Distinct Clinicopathological Features of HER2-Negative, HER2-Low, and HER2-Overexpressing Urothelial Carcinoma in a Large Chinese Cohort.

Shanshan Wang, Dingwei Ye, Li Yang

|Nov 25, 2024
Dissecting the Implications of Calumenin in Malignancy and Heterogeneity of the Microenvironment of Clear Cell Renal Cell Carcinoma Using Multi-Omics Data.

Xin-Qiang Wu, Zhi Shang, Cui Xiong

Pageof 3

Frequent Collaborators

3 joint publications

Wenhao Xu

2 joint publications

Zhe Hong

2 joint publications

Chenji Wang

1 joint publications

Xin-Qiang Wu